



In the News

Update to Commercial and ACA Medical Benefit Product Coverage for Medical Mutual Plans

Effective May 1, 2023, prior authorization will be required for Lupron Depot (leuprolide acetate) [HCPCS codes J1950, J9217] under the commercial and ACA medical benefit. Trial of Eligard will be required for the following indications under this criteria:

- Prostate Cancer
- Ovarian Cancer
- Breast Cancer
- Head and Neck Cancer – Salivary Gland Tumors

For more information, please visit [Medmutual.com/For-Providers, Policies and Standards, Corporate Medical Policies](https://www.medmutual.com/For-Providers, Policies and Standards, Corporate Medical Policies).